Abstract
Pancreatic cancer is hallmarked by aggressive biology and extreme lethality and very high mortality rates. The underlying molecular mechanism of its rapid development and progression is unclear, however. Recent identification and functional validation of nitric oxide (NO) production in pancreatic cancer suggest a role for NO in the pathogenesis of this disease. Conceivably, overproduction of NO imposes an adverse selection pressure on the tumor microenvironment, which causes genetic and epigenetic changes in tumor and tumor stromal cells and promotes the evolution of these cells into more malignant cells conferred with a tremendous survival and growth advantage. Designing effective strategies targeting NO to control pancreatic cancer development and progression requires a full understanding of the molecular mechanisms of signaling of NO production and action in the tumor microenvironment.
Keywords: NO, signaling pathway, prevention, treatment, metastasis, progression, pancreas
Current Pharmaceutical Design
Title: Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Volume: 16 Issue: 4
Author(s): Liwei Wang and Keping Xie
Affiliation:
Keywords: NO, signaling pathway, prevention, treatment, metastasis, progression, pancreas
Abstract: Pancreatic cancer is hallmarked by aggressive biology and extreme lethality and very high mortality rates. The underlying molecular mechanism of its rapid development and progression is unclear, however. Recent identification and functional validation of nitric oxide (NO) production in pancreatic cancer suggest a role for NO in the pathogenesis of this disease. Conceivably, overproduction of NO imposes an adverse selection pressure on the tumor microenvironment, which causes genetic and epigenetic changes in tumor and tumor stromal cells and promotes the evolution of these cells into more malignant cells conferred with a tremendous survival and growth advantage. Designing effective strategies targeting NO to control pancreatic cancer development and progression requires a full understanding of the molecular mechanisms of signaling of NO production and action in the tumor microenvironment.
Export Options
About this article
Cite this article as:
Wang Liwei and Xie Keping, Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment, Current Pharmaceutical Design 2010; 16 (4) . https://dx.doi.org/10.2174/138161210790232194
DOI https://dx.doi.org/10.2174/138161210790232194 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Microvascular Dysfunction and Heart Failure with Preserved
Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Design and Development of Nanoemulsion Systems Containing Interferon Gamma
Protein & Peptide Letters Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition
Current Medicinal Chemistry Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors
Medicinal Chemistry From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Interaction of Probenecid with the Breast Cancer Resistance Protein Transporter (BCRP/ABCG2)
Letters in Drug Design & Discovery VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Mucosal Immunisation: Adjuvants and Delivery Systems
Current Drug Delivery Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators
Medicinal Chemistry Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Editorial [Hot Topic: MicroRNA Regulation and its Biological Significance in Personalized Medicine and Aging (Guest Editor: Eugenia Wang)]
Current Genomics